Revive Therapeutics Announces Proposed Shares for Debt Transaction

Core Viewpoint - Revive Therapeutics Ltd. is proposing to settle $150,000 in payables through the issuance of up to 6,000,000 common shares at a price of $0.025 per share to preserve cash for ongoing operations [1][2]. Group 1: Financial Transaction - The proposed Shares for Debt Transaction aims to settle outstanding payables while maintaining cash flow for the company's operations [2]. - The issue price of $0.025 per share is based on the 20-day volume-weighted average price (VWAP) of the shares traded on the Canadian Securities Exchange (CSE) [1]. - The common shares issued will be subject to a hold period of four months and one day from the date of issuance [2]. Group 2: Company Overview - Revive Therapeutics is focused on the research and development of therapeutics for infectious diseases, rare disorders, and medical countermeasures [1][3]. - The company is exploring the use of Bucillamine for potential treatments related to nerve agent exposure and long COVID, and is advancing the development of Psilocybin and molecular hydrogen therapeutics [3]. - Revive Therapeutics aims to leverage various regulatory incentives from the FDA, including Emergency Use Authorization and Orphan Drug designations, to enhance its drug development efforts [3].